Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Cancer Letters
|
November 28, 2025
Corrigendum to "Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis" [Cancer Letters 633 (2025) 217990]
Chandrayee Ghosh, Tejinder Pal Khaket, Viswanath Gunda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2018
Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer <i>In Vitro</i> and <i>In Vivo</i>
Shilpa Thakur, Brianna Daley, Kelli Gaskins, et al.
Cancer Research
|
April 29, 2010
Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells
Rabii Ameziane-El-Hassani, Myriem Boufraqech, Odile Lagente-Chevallier, et al.
Molecular Carcinogenesis
|
February 27, 2024
Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer
Takashi Furusawa, Renzo Cavero, Yue Liu, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 16, 2014
Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype
Ryan J Ellis, Yonghong Wang, Holly S Stevenson, et al.
Cancer Letters
|
August 20, 2025
Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis
Chandrayee Ghosh, Tejinder Pal Khaket, Viswanath Gunda, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 1, 2023
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors
Haojian Li, Yue Liu, Yunjie Xiao, et al.
Cancer Research
|
December 10, 2014
miR30a inhibits LOX expression and anaplastic thyroid cancer progression
Myriem Boufraqech, Naris Nilubol, Lisa Zhang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
September 23, 2022
Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
Dipranjan Laha, Robert R C Grant, Prachi Mishra, et al.
Nature Communications
|
February 16, 2016
The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition
Urbain Weyemi, Christophe E Redon, Rohini Choudhuri, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Cancer Letters
|
November 28, 2025
Corrigendum to "Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis" [Cancer Letters 633 (2025) 217990]
Chandrayee Ghosh, Tejinder Pal Khaket, Viswanath Gunda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 26, 2018
Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer <i>In Vitro</i> and <i>In Vivo</i>
Shilpa Thakur, Brianna Daley, Kelli Gaskins, et al.
Cancer Research
|
April 29, 2010
Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells
Rabii Ameziane-El-Hassani, Myriem Boufraqech, Odile Lagente-Chevallier, et al.
Molecular Carcinogenesis
|
February 27, 2024
Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer
Takashi Furusawa, Renzo Cavero, Yue Liu, et al.
The Journal of Clinical Endocrinology and Metabolism
|
January 16, 2014
Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype
Ryan J Ellis, Yonghong Wang, Holly S Stevenson, et al.
Cancer Letters
|
August 20, 2025
Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis
Chandrayee Ghosh, Tejinder Pal Khaket, Viswanath Gunda, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 1, 2023
CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors
Haojian Li, Yue Liu, Yunjie Xiao, et al.
Cancer Research
|
December 10, 2014
miR30a inhibits LOX expression and anaplastic thyroid cancer progression
Myriem Boufraqech, Naris Nilubol, Lisa Zhang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
September 23, 2022
Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
Dipranjan Laha, Robert R C Grant, Prachi Mishra, et al.
Nature Communications
|
February 16, 2016
The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition
Urbain Weyemi, Christophe E Redon, Rohini Choudhuri, et al.
Page
of 5